XML 29 R15.htm IDEA: XBRL DOCUMENT
v3.25.1

Note 8 - Accrued Liabilities | 12 Months Ended
--- | ---
Jun. 30, 2025
Notes to Financial Statements |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 8 - Accrued liabilities Accrued liabilities consist of the following:
​ |  | June 30, |
​ |  | 2024 |  |  | 2023 |
​ |  | (in thousands) |
Accrued savings offers |  | $ | 11,054 |  |  | $ | 15,739 |
Accrued program liabilities |  |  | 9,964 |  |  |  | 11,012 |
Accrued customer and product related fees |  |  | 5,395 |  |  |  | 6,579 |
Accrued compensation |  |  | 4,603 |  |  |  | 5,299 |
Return reserve |  |  | 4,832 |  |  |  | 5,683 |
Other accrued liabilities |  |  | 2,295 |  |  |  | 1,650 |
Total accrued liabilities |  | $ | 38,143 |  |  | $ | 45,962 |
Accrued savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. Accrued program liabilities include government and commercial rebates. Accrued customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. Accrued employee compensation includes sales commissions, paid time off earned, accrued payroll and accrued bonus. The return reserve represents the Company’s accrual for estimated product returns. Other accrued liabilities consist of various other accruals, none of which individually or in the aggregate represent greater than five percent of total liabilities. The following table details the change in return reserve for the periods presented:
​ |  | Return Reserve |
​ |  | (in thousands) |
Balance, June 30, 2022 |  | $ | 5,559 |
Reduction of net revenue |  |  | 6,785 |
Payments |  |  | (6,661 | )
Balance, June 30, 2023 |  |  | 5,683 |
Reduction of net revenue |  |  | 5,838 |
Payments |  |  | (6,689 | )
Balance, June 30, 2024 |  | $ | 4,832 |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration